Wall Street brokerages expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to post ($0.40) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Corvus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.39). Corvus Pharmaceuticals posted earnings per share of ($0.58) in the same quarter last year, which would indicate a positive year-over-year growth rate of 31%. The company is scheduled to announce its next earnings results on Thursday, March 7th.

On average, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($1.81) to ($1.74). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.59) per share, with EPS estimates ranging from ($1.65) to ($1.52). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, November 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.12.

A number of equities research analysts have recently commented on the company. Zacks Investment Research raised Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Monday, January 14th. BidaskClub lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 21st. Cowen reaffirmed a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Friday, November 2nd. Finally, ValuEngine lowered Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $12.25.

Shares of NASDAQ CRVS traded up $0.08 during mid-day trading on Monday, reaching $4.12. 51,754 shares of the company’s stock were exchanged, compared to its average volume of 151,822. The firm has a market cap of $118.30 million, a P/E ratio of -1.51 and a beta of 0.90. Corvus Pharmaceuticals has a twelve month low of $3.22 and a twelve month high of $13.91.

In other news, CEO Richard A. Md Miller bought 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 27th. The shares were acquired at an average price of $3.29 per share, with a total value of $65,800.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Richard A. Md Miller bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, December 20th. The stock was purchased at an average cost of $4.40 per share, for a total transaction of $44,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 81,202 shares of company stock worth $316,992. 39.50% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in CRVS. BlackRock Inc. raised its position in Corvus Pharmaceuticals by 51.9% in the 2nd quarter. BlackRock Inc. now owns 1,119,507 shares of the company’s stock valued at $12,290,000 after buying an additional 382,389 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Corvus Pharmaceuticals by 66.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 260,701 shares of the company’s stock valued at $2,237,000 after buying an additional 104,230 shares during the last quarter. Renaissance Technologies LLC raised its position in Corvus Pharmaceuticals by 22.2% in the 3rd quarter. Renaissance Technologies LLC now owns 396,900 shares of the company’s stock valued at $3,405,000 after buying an additional 72,000 shares during the last quarter. Northern Trust Corp increased its position in shares of Corvus Pharmaceuticals by 69.2% during the 2nd quarter. Northern Trust Corp now owns 149,846 shares of the company’s stock worth $1,645,000 after purchasing an additional 61,276 shares during the last quarter. Finally, Hikari Power Ltd acquired a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $275,000. 87.42% of the stock is currently owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Story: Inflation

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.